Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
1(9%)
Results Posted
0%(0 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_1
6
55%
Ph phase_2
5
45%

Phase Distribution

6

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
6(54.5%)
Phase 2Efficacy & side effects
5(45.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

30.0%

3 of 10 finished

Non-Completion Rate

70.0%

7 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(3)
Terminated(7)

Detailed Status

Withdrawn5
Completed3
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (54.5%)
Phase 25 (45.5%)

Trials by Status

withdrawn545%
completed327%
active_not_recruiting19%
terminated218%

Recent Activity

1 active trials
Showing 5 of 11
active_not_recruitingphase_2

A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

NCT03793140
withdrawnphase_2

CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer

NCT03374852
withdrawnphase_1

CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

NCT05070104
withdrawnphase_1

CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome

NCT03929211
completedphase_1

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01768897
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT03793140Phase 2

A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

Active Not Recruiting
NCT03374852Phase 2

CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer

Withdrawn
NCT05070104Phase 1

CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Withdrawn
NCT03929211Phase 1

CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome

Withdrawn
NCT01768897Phase 1

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed
NCT01034475Phase 1

Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies

Completed
NCT00907166Phase 1

A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients

Terminated
NCT00741403Phase 1

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

Completed
NCT01520805Phase 2

Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

Withdrawn
NCT01832857Phase 2

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

Terminated
NCT01830322Phase 2

Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer

Withdrawn

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11